NCT07823855Recruiting
SIB Accelerated Hyperfractionated RT for High-Proliferation NSCLC
A Single-arm Phase I/II Clinical Study of Simultaneous Integrated Boost Accelerated Hyperfractionated Radiotherapy for High-proliferation Non-small Cell Lung Cancer
Source: ClinicalTrials.gov · Last updated 16 Sept 2026
Brief summary (registry, in English)
This is a prospective, single-arm, single-center phase I/II clinical trial evaluating the safety, objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) of simultaneous integrated boost accelerated hyperfractionated radiotherapy in patients with high-proliferation non-small cell lung cancer (NSCLC).
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- First submitted
- 4 Aug 2026
- Start date
- 16 Jun 2026
- Primary completion date
- 16 Jun 2028
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Diseases
- Lung cancer
- NCT number
- NCT07823855
What you commit to
- Study type: Interventional
- Planned participants: 15
- From 16 Jun 2026 to the primary completion date, 16 Jun 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent participation in other interventional clinical trials;
Other illness
- Severe cardiac disease (New York Heart Association \[NYHA\] functional class ≥ III, uncontrolled arrhythmia, or myocardial infarction within the past 6 months);
- Other conditions deemed by the investigator to make the patient unsuitable for enrollment (e.g., severe mental illness).
Other
- Small cell histology;
- Pregnant or breastfeeding women, or patients of childbearing potential who are unwilling to use effective contraceptive measures;
Who the study is looking for
- Age ≥ 18 years, male or female;
- Histologically or cytologically confirmed high-proliferation non-small cell lung cancer (NSCLC);
- Assessed by a multidisciplinary team (MDT) and planned to receive thoracic radiotherapy (either curative or palliative), regardless of stage.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| 2nd Affiliated Hospital, School of Medicine, Zhejiang University Coordinator of this site? Confirm its status | Hangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.